Science & Technology

CancerSpot: DNA Methylation and Blood-Based Cancer Detection

CancerSpot: DNA Methylation and Blood-Based Cancer Detection

Why in news?

A study of blood-based cancer detection has examined how DNA fragments in blood relate to cancer-associated signals. The Hindu reported the findings on 18 November 2026. The research forms part of work on CancerSpot, a test developed by Bengaluru-based Strand Life Sciences.

The study, published in the Proceedings of the National Academy of Sciences, included 1,480 participants recruited across 43 Indian hospitals. They included patients with clinically detected cancers of 14 types, people with benign growths and healthy volunteers. Higher total cell-free DNA levels were associated with stronger cancer-related methylation signals.

DNA fragments in blood

Deoxyribonucleic acid (DNA) carries genetic information in cells. Dying cells release small fragments of DNA into the bloodstream. DNA circulating outside cells is called cell-free DNA (cfDNA).

The circulating pool contains material from several cell types, including immune cells. The part originating from tumour cells is called circulating tumour DNA (ctDNA).

A liquid biopsy examines tumour-related material in a body fluid, such as blood. DNA analysis can look for molecular features associated with cancer.

What methylation reveals

DNA methylation adds chemical tags called methyl groups at particular sites on DNA. These tags can influence how genes are used. Cancer cells can have methylation patterns that differ from those of normal cells.

CancerSpot combines DNA sequencing with computer-based analysis of methylation patterns. The aim is to identify cancer-associated signals in the DNA mixture. In this study, stronger signals accompanied higher total cfDNA levels even within cancer-stage groups.

Reading test-performance figures

The Hindu reported 72% sensitivity and a 1.4% false-positive rate in a validation group. Sensitivity measures the share of people with cancer who test positive. The false-positive rate measures the share of people without cancer who nevertheless test positive.

Conclusion

Study co-author Sewanti Limaye called for further independent validation before translating the finding into screening strategies. Such studies can assess early-diagnosis benefits and patient outcomes.

Sources

Lead image: Clarity UPSC AI illustration of representative laboratory sample handling.

Daily news News Blitz Daily quiz Prelims PYQs Live Economic Data Subject notes How to prepare for UPSC Books and NCERTs Syllabus Exam pattern Eligibility and attempts Previous Year Papers Free Downloads Shorts Sign in